Sign In
Buy ATHX
$0.0135
+0 (+0%)
At Close: Apr 05, 2024
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
08:00am, Friday, 11'th Aug 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neem
Athersys to Host Business Update Conference Call on August 9th
01:38pm, Monday, 31'st Jul 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wil
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollme
Athersys Restructures Debt with Supplier
08:30am, Tuesday, 23'rd May 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructur
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
09:58am, Thursday, 18'th May 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 1
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
08:30am, Monday, 01'st May 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their part
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
02:23pm, Friday, 21'st Apr 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their part
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
04:01pm, Wednesday, 19'th Apr 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company's common stock
Athersys to Host Business Update Conference Call on April 20th
03:29pm, Monday, 10'th Apr 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wil
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
03:00pm, Monday, 06'th Mar 2023 Benzinga
Upgrades
Goldman Sachs upgraded the previous rating for iQIYI Inc (NASDAQ:IQ) from Neutral to Buy. iQIYI earned $0.14 in the fourth quarter, compared to $0.35 in the year-ago quarter. At the moment, t
Athersys to Host Business Update Conference Call on February 14th
08:30am, Thursday, 02'nd Feb 2023
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it w
Why Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving Premarket
11:23am, Thursday, 15'th Dec 2022 Benzinga
Gainers
Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday.
Surrozen, Inc. (NASDAQ: SRZN) shares rose 67.3% to $0.7291 in pre-mark
Why Elbit Systems Shares Are Trading Lower By Over 10%; Here Are 24 Stocks Moving Premarket
12:28pm, Tuesday, 29'th Nov 2022 Benzinga
Gainers
NanoVibronix, Inc. (NASDAQ: NAOV) shares rose 26.3% to $0.7994 in pre-market trading after the company received FDA 510K premarket clearance for PainShield Plus, its dual-actuator ultrasound
Athersys, Inc. (ATHX) Q3 2022 Earnings Call Transcript
04:19pm, Tuesday, 15'th Nov 2022
Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan Camardo – Chief
